Search - tctmd.com

Displaying 21 - 40 of 300

Sort: Relevancy | Date

Presentation TCT 2022

TCT 14: A 30-day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) Post PCI in Brazil and Japan : SYNERGY Stent with Prasugrel Monotherapy (10 or 3.75 mg )

Presenter: Yoshinobu Onuma

September 17, 2022

Presentation TCT 2022

TCT 13: Ticagrelor Monotherapy in Patients With Peripheral Artery Disease Undergoing PCI

Presenter: Alessandro Spirito

September 17, 2022

Presentation TCT 2022

TCT 29: Platelet Reactivity and Clinical Outcomes After Drug-Eluting Stent Implantation in East Asian Patients with Diabetes: Results From the PTRG-DES Registry

Presenter: KI-HYUN JEON

September 17, 2022

Presentation TCT 2022

TCT 28: Pharmacodynamic response, early reperfusion and clinical outcomes to pre-hospital prasugrel administration in diabetic patients presenting with STEMI – A COMPARE CRUSH subanalysis

Presenter: Rosanne Vogel

September 17, 2022

Presentation TCT 2022

TCT 27: Ticagrelor versus Prasugrel in an All-Comer Patient Cohort undergoing Percutaneous Coronary Intervention

Presenter: Anoop Koshy

September 17, 2022

Presentation TCT 2022

TCT 26: Efficacy and Safety of Ticagrelor Compared to Clopidogrel in Elderly Patients With ST-Elevation Myocardial Infarction

Presenter: André Luz

September 17, 2022

Presentation TCT 2022

TCT 24: Ticagrelor versus Prasugrel in Acute Myocardial Infarction for East Asians

Presenter: Ji sung KIM

September 17, 2022

Presentation TCT 2022

TCT 23: Influence of the circadian clock on the pharmacodynamic effect of prasugrel in patients presenting with ST-segment elevation myocardial infarction – A COMPARE CRUSH subanalysis

Presenter: Rosanne Vogel

September 17, 2022

Presentation TCT 2022

TCT 22: Clopidogrel versus Aspirin in the Chronic Maintenance Period Following Percutaneous Coronary Intervention in Patients with Acute Coronary syndrome: Subgroup Analysis of the HOST-EXAM trial

Presenter: Jeehoon Kang

September 17, 2022

Presentation TCT 2022

TCT 21: Preferred Strategy in the Era of Short-Term Dual Antiplatelet Therapy: A Systematic Review and Network Meta-Analysis of Randomized Trials

Presenter: Toshiki Kuno

September 17, 2022

Presentation TCT 2022

TCT 20: Relative benefit of double versus triple antithrombotic therapy in patients with atrial fibrillation randomized earlier versus later after index coronary event: Insights from the AUGUSTUS Trial

Presenter: Alexander Fanaroff

September 17, 2022

Presentation TCT 2022

TCT 19: Thrombin Generation and Endothelial Progenitor Cell Function in Patients with Acute Myocardial Infarction Treated with Prasugrel versus Ticagrelor

Presenter: Mark Kheifets

September 17, 2022

News Conference News ACC 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

Michael O'Riordan

April 12, 2022

News Conference News ACC 2022

Bentracimab Swiftly Reverses Ticagrelor, Platelet-Function Study Affirms

Todd Neale

April 02, 2022

News Conference News AHA 2021

Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data

Yael L. Maxwell

November 15, 2021

News Conference News AHA 2021

RAPID CABG: No Penalty to Early Surgery for ACS After Stopping Ticagrelor

Yael L. Maxwell

November 13, 2021

News Daily News

Lidocaine Less Likely Than Fentanyl to Blunt P2Y12 Inhibitors in the Cath Lab

L.A. McKeown

September 07, 2021

News

Tastes Like Ticagrelor: Mouth-Dissolving Pills Match Standard Ones in ACS

Yael L. Maxwell

July 13, 2021

Crushing Prasugrel Tabs Ups Platelet Inhibition Following Primary PCI

News Daily News

Crushed Prasugrel in the Ambulance Ups Platelet Inhibition in Primary PCI

Yael L. Maxwell

June 22, 2021

News Daily News

New Antithrombotic Revacept Fails to Reduce Myocardial Injury in PCI

Yael L. Maxwell

April 05, 2021

Advertisement

TCT 14: A 30-day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) Post PCI in Brazil and Japan : SYNERGY Stent with Prasugrel Monotherapy (10 or 3.75 mg )

TCT 13: Ticagrelor Monotherapy in Patients With Peripheral Artery Disease Undergoing PCI

TCT 29: Platelet Reactivity and Clinical Outcomes After Drug-Eluting Stent Implantation in East Asian Patients with Diabetes: Results From the PTRG-DES Registry

TCT 28: Pharmacodynamic response, early reperfusion and clinical outcomes to pre-hospital prasugrel administration in diabetic patients presenting with STEMI – A COMPARE CRUSH subanalysis

TCT 27: Ticagrelor versus Prasugrel in an All-Comer Patient Cohort undergoing Percutaneous Coronary Intervention

TCT 26: Efficacy and Safety of Ticagrelor Compared to Clopidogrel in Elderly Patients With ST-Elevation Myocardial Infarction

TCT 24: Ticagrelor versus Prasugrel in Acute Myocardial Infarction for East Asians

TCT 23: Influence of the circadian clock on the pharmacodynamic effect of prasugrel in patients presenting with ST-segment elevation myocardial infarction – A COMPARE CRUSH subanalysis

TCT 22: Clopidogrel versus Aspirin in the Chronic Maintenance Period Following Percutaneous Coronary Intervention in Patients with Acute Coronary syndrome: Subgroup Analysis of the HOST-EXAM trial

TCT 21: Preferred Strategy in the Era of Short-Term Dual Antiplatelet Therapy: A Systematic Review and Network Meta-Analysis of Randomized Trials

TCT 20: Relative benefit of double versus triple antithrombotic therapy in patients with atrial fibrillation randomized earlier versus later after index coronary event: Insights from the AUGUSTUS Trial

TCT 19: Thrombin Generation and Endothelial Progenitor Cell Function in Patients with Acute Myocardial Infarction Treated with Prasugrel versus Ticagrelor

Managing AF Patients Undergoing PCI—Some Lingering Questions

Bentracimab Swiftly Reverses Ticagrelor, Platelet-Function Study Affirms

Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data

RAPID CABG: No Penalty to Early Surgery for ACS After Stopping Ticagrelor

Lidocaine Less Likely Than Fentanyl to Blunt P2Y12 Inhibitors in the Cath Lab

Tastes Like Ticagrelor: Mouth-Dissolving Pills Match Standard Ones in ACS

Crushed Prasugrel in the Ambulance Ups Platelet Inhibition in Primary PCI

New Antithrombotic Revacept Fails to Reduce Myocardial Injury in PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content